Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 231

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 231
---
able for shares of our capital stock in
any “at-the-market”, continuous equity or variable rate transaction, without the prior written consent of the
Representative.

Right of First Refusal

We will grant the Representative
a right of first refusal, for a period of 36 months from the closing of the offering, to act as sole investment banker, sole book-runner
and/or sole placement agent, at the Representative’s sole discretion, for each and every future public and private equity and debt
offering, including all equity linked financings, during such 36-month period, for us, or any successor to or any subsidiary of us, on
terms customary for the Representative. The Representative will have the sole right to determine whether any other broker-dealer shall
have the right to participate in any such offering and the economic terms of any such participation. any other broker-dealer shall have
the right to participate in any such offering and the economic terms of any such participation.

<div align='center'>137</div>

Pricing of the Offering

Prior to this offering, there
was no established public market for our Ordinary Shares. The public offering price will be negotiated between us and the underwriters.
In determining the price, we will consider our history and prospects, our business potential and earnings prospects, an assessment of
our management, general securities market conditions at the time of the offering, and such other factors that we deem relevant.

An active trading market
for our Ordinary Shares may not develop. It is also possible that the Ordinary Shares will not trade in the public market or above the
initial public offering price following the closing of this offering.

Indemnification

We have agreed to indemnify
the underwriters and their affiliates, stockholders, directors, officers, employees, members and controlling persons (within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act) against all losses, claims, damages, expenses and liabilities,
as the same are incurred (including the reasonable fees and expenses of counsel), relating to or arising out of its activities hereunder
or pursuant to this engagement letter, undertaken in good faith.

Electronic Offer, Sale and Distribution of Shares

This prospectus in electronic
format may be made available on websites or through other online services maintained by one or more of the underwriters, or by their
affiliates. Other than this prospectus in electronic format, the information on any underwriter’s website and any information contained
in any other website maintained by